drugset / Trial / NCT06947226

A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors

NCT06947226

Phase 1/2 Not yet recruiting 188 enrolled Mabwell (Shanghai) Bioscience Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is a Phase Ib/ll, open-label, multicenter study designed to evaluate the safety and efficacy of 9MW2821 monotherapy or combined with other anticancer therapy in advanced solid tumors.

Timeline

Start
2025-04
Primary completion
2026-04
Completion
2027-04

Drugs

EvaluationDrugModalityDoseRoute
Subject 9MW2821 Monoclonal antibody Intravenous

Indications